RiskManagement
-
Stop Treating Cramer Calls Like Gospel — Marvell’s Crowded, Bausch Is a Gamble
Fade or Follow? Cramer’s Bullish Take on Marvell — and the Murky Bausch Call When Jim Cramer shouts “buy,” you’ve got two choices: grab a seat on the rocket or start looking for the exit. With Marvell riding the AI wave and Bausch Health limping through its turnaround, blindly following either call isn’t a strategy.…
-
Stop Trading Like a Fan: If You’re Buying MRVL or BHC, Bring a Plan
Jim Cramer says buy Marvell (MRVL) and Bausch Health (BHC). Fine. But blindly following TV calls is how you end up bag-holding someone else’s conviction. If you’re going to play these, you need levels. You need risk control. And you need a plan for when the story cracks. Let’s break it down like a trader,…
-
Cramer’s Buy Calls Aren’t Alpha — They’re Exit Liquidity
Jim Cramer says buy Marvell and Bausch Health. The real question isn’t whether he’s bullish — it’s whether you should be. Because in 2024, a Cramer buy call isn’t just a recommendation. For some traders, it’s a contrarian indicator. Let’s break this down. Marvell (MRVL): AI Tailwinds — But You’re Paying for Them Marvell is…
-
Buying the Bounce Is Not a Strategy — And Cramer’s Picks Prove It
Jim Cramer says buy Marvell and Bausch Health. Fine. But are these actually smart entries right now — or just classic “it’s been crushed, so it must bounce” trades? Let’s separate signal from noise. Marvell (MRVL): Riding the AI Wave — But Timing Matters Marvell isn’t some speculative chip name. It’s a serious data infrastructure…
You must be logged in to post a comment.